RECOMMENDATIONS AND GUIDELINES
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

https://doi.org/10.1111/jth.14935Get rights and content
Under an Elsevier user license
open archive

Abstract

Clarity and guidance is required with regard to the use of direct oral anticoagulants in antiphospholipid syndrome (APS) patients, within the confines of the recent European Medicines Agency recommendations, discrepant recommendations in other international guidelines and the limited evidence base. To address this, the Lupus Anticoagulant/Antiphospholipid Antibodies Scientific and Standardization Committee (SSC) chair and co‐chairs together with SSC Control of Anticoagulation members propose guidance for healthcare professionals to help them manage APS patients. Uncertainty in this field will be addressed. This guidance will also serve as a call and focus for research.

Keywords

antiphospholipid antibodies
antiphospholipid syndrome
arterial thrombosis
direct oral anticoagulants
triple positivity
venous thromboembolism
vitamin K antagonists

Cited by (0)

Stéphane Zuily and Hannah Cohen are co‐first authors.

Stéphane Zuily, Hannah Cohen, and Katrien M. J. Devreese are SSC Lupus Anticoagulant/Antiphospholipid Antibodies members.

Mark Crowther and Adam Cuker are SSC Control of Anticoagulation members.

Manuscript handled by: Marcel Levi

Final decision: 18 May 2020